Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer CenterRoland B. Walter, Elihu H. Estey, Alan K. Burnett et al.|Leukemia|2014Cited by 172
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Hagop Kantarjian, Peter F. Thall et al.|Haematologica|2015Cited by 121
A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic LeukemiaHannah Goulart, Nitin Jain, Tapan M. Kadia et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 8
ALL-808 Very Promising Results of the Dose Dense (D-D) Mini-Hyper-CVD-Inotuzumab-Blinatumomab Phase 2 Trial in Patients with Relapsed-Refractory Acute Lymphoblastic LeukemiaElias Jabbour, Hagop Kantarjian, Fadi Haddad et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 7